One of the most important cancer breakthroughs of the year may have just arrived. Researchers publishing in the New England Journal of Medicine found that daraxonrasib significantly outperformed standard chemotherapy in patients with metastatic pancreatic cancer carrying the KRAS G12D mutation. Why does this matter? KRAS mutations are among the most common drivers of cancer, yet they have historically been incredibly difficult to target with drugs. Pancreatic cancer is also one of the most lethal cancers, with limited treatment options once it progresses. This study suggests that directly targeting KRAS G12D could become a powerful new strategy in the fight against pancreatic cancer. We are entering an era where cancer treatment is becoming increasingly personalized, targeting the specific genetic mutations that drive disease rather than relying solely on broad-spectrum chemotherapy. The future of oncology is precision medicine. #Cancer #PancreaticCancer #FuckCancer #NEJM #Macr...